The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To be honest this company doesn't need a new RNS to be valued much more highly than it is right now. I imagine that this week's activity has alerted a few folk to it and the lack of liquidity has meant the price responds very quickly. But people who didn't know about it went and read up and saw that the most recent deal for rapid acting insulin was ~£500m and Novo bought a Bristol based start-up for £800m . And that's just one part of Arecor's diabetes technology, let alone the other bits.
Code 1 and 0 wonder if we have an rns coming?
Company is way too cheap for the products they have offer!!
Something is brewing
310/326
Spread has narrowed,hopefully it might entice a few to buy!!
Actually buy has ticked up to 3.23 and sell has ticked up a tad to 3.075 , thereby true spread is only 5% and tightening!!
The spread is now 11% and there's virtually no liquidity. It's not going to move much until there's some new news.
Amazed this is sitting on this price after yesyerdays great news
Bid and sell ticking up slightly!!
Interesting results and potentially a takeover target!!
Just bought in as i think this could be huge for the company
Gla
£100m and still vastly undervalued. Not sure which part of the business will be bigger, the insulin and diabetes activities or all the other drugs that need injection and are better if you can just have them as a concentrated liquid (i.e. a smaller injection) stored at room temperature .
Now the insulin side has all been tested in animals and it has translated beautifully to humans, but the other part of the business has already been accumulating licenses with very handsome royalty rates and or license fees.
Sarah Howell, Chief Executive Officer of Arecor, said: "The successful completion of our AT278 Phase I clinical trial is an important milestone for Arecor. AT278 has the potential to disrupt the market for insulin treatment in people with diabetes, as the first concentrated, yet rapid acting, insulin - a critical enabler in the development of next generation miniaturised insulin delivery systems. The study had been designed to achieve PK/PD equivalence with a comparable dose of lower concentration NovoRapid®. The achievement of a superior PK/PD profile goes beyond our expectations and for that we are delighted.
CEO said this will disrupt the diabetes drug market
Enough said!!
Can’t buy a bean. They need to put the price up ;)
SING moved to 390
No stock about
320 paid let’s see what happens today :)
Cant buy a bean again on HL.
MM's could have an issue here
Level 2
SING just moved to 354p
It’s happening
Same here, i went in at 2.80 and paid 2.94
Buy and hold on tightly. This is not a stock to trade. I believe this company is going places
Yes was a struggle, I had to do a fill or kill.
There are only 3MM on this share with a market size of 1000
That means with a bit of volume this will have a violent swing up
Stay tuned
Have you tried buying any? took nearly 1 hour to get some
AT278 has the potential to disrupt the market for insulin treatment in people with diabetes, as the first concentrated, yet rapid acting, insulin - a critical enabler in the development of next generation miniaturised insulin delivery systems.
Seems like market has missed this gem.. but for how long till discovered?